Immunogen (IMGN) Reports Q4 Loss of $0.17/sh

Immunogen (NASDAQ: IMGN) reported Q4 EPS of ($0.17), versus $0.16 reported last year. Revenue for the quarter came in at $28 million, versus $85.8 million reported last year.

GUIDANCE:

Immunogen sees 2022 revenue of $75-85 million.

• revenues between $75 million and $85 million;
• operating expenses between $285 million and $295 million; and
• cash and cash equivalents at December 31, 2022, to be between $245 million and $255 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c